Company intelligence / Profile preview

CanTx Biosciences

Weston, Florida, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Cantex is conducting Phase 2 clinical trials investigating azeliragon in combination with radiation therapy with or without temozolomide in newly diagnosed glioblastoma[3]. The company received FDA Orphan Drug Designation for azeliragon for brain metastasis from breast cancer in December 2024[3] and for pancreatic cancer in May 2024[3]. Four abstracts featuring azeliragon were presented at the 2024 ASCO Annual Meeting[3].

Therapeutic areas: OncologyPulmonologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on CanTx Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CanTx Biosciences.

Explore the full profile